Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Histatin Stimulates Proliferation in Human Primary Corneal Endothelial Cells
Author Affiliations & Notes
  • Ramkumar Srinivasagan
    Visus Therapeutics, Irvine, California, United States
  • Patrick Hughes
    Visus Therapeutics, Irvine, California, United States
  • James Burke
    Visus Therapeutics, Irvine, California, United States
  • Rhett Schiffman
    Visus Therapeutics, Irvine, California, United States
  • Footnotes
    Commercial Relationships   Ramkumar Srinivasagan Visus Therapeutics, Code E (Employment); Patrick Hughes Visus Therapeutics, Code E (Employment); James Burke Visus Therapeutics, Code E (Employment); Rhett Schiffman Visus Therapeutics, Code E (Employment)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4143. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ramkumar Srinivasagan, Patrick Hughes, James Burke, Rhett Schiffman; Histatin Stimulates Proliferation in Human Primary Corneal Endothelial Cells. Invest. Ophthalmol. Vis. Sci. 2024;65(7):4143.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Histatins are low molecular weight salivary and lacrimal peptides with wound healing, anti-inflammatory, anti-apoptotic, and antimicrobial properties. In a rabbit model of anterior keratectomy, topically administered histatin-1 accelerated epithelial wound repair, inhibited and restored loss of stromal keratocytes and corneal endothelial cells, and stimulated regeneration of corneal nerves (Burke, ARVO 2022). Histatin-1 also markedly decreased endothelial cell loss under stressed temperature conditions in donor human cornea buttons and reduced associated biomarkers of apoptosis (Sawant, ARVO 2023). We examined whether histatin-1 could stimulate growth of human corneal endothelial cells as a potential therapy for corneal endothelial dystrophies.

Methods : Human primary corneal endothelial cells were grown for 24 hrs in 10% serum in coated 6-well tissue plates to 90% confluency. A single scratch was made in each well, then low serum media (1%) was added with histatin-1 concentrations ranging from 1x10-9M to 1x10-5M or PBS as a control. Cells were incubated for up to 48 hours. Cell proliferation was determined at 24 and 48 hours using the Click-iT EdU Assay (Thermo Fisher). Imaging software was used to quantify the percent of scratch area regenerated or EDU-stained cell counts.

Results : Histatin-1 increased the rate of regeneration (migration or proliferation) over PBS control at all 3 incubation times. Maximal efficacy was at 1x10-8 M for all 3 timepoints, and were 120%, 93% and 77% over PBS control for 6 hrs, 24 hrs and 48 hrs, respectively. This increase in regeneration in the scratch area was associated with concentration-related increases in proliferation based on EDU-stained cell counts. The percentage change over PBS control for 1x10-9M to 1x10-5M histatin-1 ranged from 7% to 48% at 24 hrs and from 12% to 130% at 48 hrs.

Conclusions : This study showed for the 1st time that histatin-1 rapidly regenerates human primary corneal endothelial cells in a wound repair setting, and that cell proliferation is a key component of the regenerative effect. These results add to a growing literature that supports a potential therapeutic utility of histatins in the eye.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

Histatin-1 increases EDU-stained cells following a scratch in confluent cultures of human primary corneal endothelial cells.

Histatin-1 increases EDU-stained cells following a scratch in confluent cultures of human primary corneal endothelial cells.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×